Japan National Overview
—
Healthcare data to drive decisions
comprehensive · accurate · accessible
Japan – Diagnostics
Real world hospital intelligence across Japanese hospitals across 8 regions
Data spanning multiple years
Location Japan
Cases (selected) 0
Hospitals (selected) 0
1
Find the disease / indication
2
Choose the region
Region volume (treated cases)
Select a disease to see regional distribution
Select a disease on the left to populate the region chart.
3
Generate outputs
Japan National Overview
✓
Pan-Japan cases, incidence, providers, trials & treatment mix across all 8 regions.
Detailed Report
✓
Single combined report covering the selected region — or Japan as a whole.
Five integrated modules + Excel hospital data
Includes
- Clinical Scope & Coding
- Treated Patient Reality
- Hospital Concentration & Tiering
- Regional Inequality & Access Signals
- Key Opinion Leaders & Market Influence
- Excel hospital data
- Clinical Scope & Coding
- Treated Patient Reality
- Hospital Concentration & Tiering
- Excel hospital data
Modules
0
—
CONTENTS
Detailed National Report
🏢 Commercial
💷 Market Access
🔬 Medical Affairs
A · Front Matter
1 – 4
Cover
1
Contents
2
Executive Summary
3
Persona Navigator
4
B · National Disease Scope
5 – 9
Disease at a glance
5
Subcode distribution (national + regional)
6
Peer ICD-10 codes
7
Coding patterns across regions
8
Indication context for Japan (web-sourced)
9
C · National Treatment Landscape
10 – 22
Volumes & trends
10
Demographics
12
Patient journey (with regional notes)
14
Hospital tiering
17
Tier composition & concentration
20
Inequality overview
21
D · KOL & Research Landscape
23 – 39
Trials in Japan at a glance 🔬
23
Top 50 hospitals by case volume 🏢
25
Top 50 KOLs by recent publications 🔬
31
Publication network
36
Active trial landscape detail
37
Strategic narrative (KOL)
39
E · The 8 Regional Dossiers
Phase 2
Coming in Phase 2 — Hokkaido, Tohoku, Kanto, Chubu, Kansai, Chugoku, Shikoku, Kyushu & Okinawa
F · Cross-Region Analytics
Phase 2
Coming in Phase 2
G · Persona Deep-Dives
Phase 3
Commercial deep-dive 🏢
Phase 3
Market Access deep-dive 💷
Phase 3
Medical Affairs deep-dive 🔬
Phase 3
H · Methods & Data Sources
40
I · Appendix
41
Glossary
Phase 2
Hospitals · Trials · KOLs delivered as a separate Excel companion
© PurpleXtra Limited
Contents
EXECUTIVE SUMMARY
Detailed National Report
Disease Snapshot
Cases: —
Hospitals: —
ICD-10: —
Geographic Distribution
47-prefecture choropleth
— placeholder, populated in subsequent session —
KOL & Research Signal
Top 3 hospitals: —
Top 3 KOLs: —
Total trials: —
Market Structure
Tier I / II / III split: —
90/10 concentration: —
Headline Disparities
— placeholder, populated in subsequent session —
Signature Charts
— miniatures of trend, tiering, inequality —
— placeholder, populated in subsequent session —
© PurpleXtra Limited
Executive Summary
PERSONA NAVIGATOR
How to read this report for your role
🏢
Commercial
Field force · Account targeting
Read for regional opportunity sizing, top hospitals to call on, and where capacity is concentrating.
Most relevant pages
- National volumes & trends
- Top 50 hospitals by volume
- Hospital tiering & concentration
- Each regional dossier (Part E)
- Inter-region league tables
- Strongest opportunities (page 93)
15-min skim
Executive Summary → Top 50 hospitals → Cross-region league table → 1 regional dossier of interest.
💷
Market Access
Regulatory · Provider concentration
Read for the regulatory picture and channel concentration. Payer-specific data not provided; what is here is publicly cited.
Most relevant pages
- Indication context for Japan
- Hospital concentration metrics
- Tier composition (national + per region)
- Market Access deep-dive (pages 97-98)
- Methods & data sources
15-min skim
Indication context → Market Access deep-dive → Capacity heatmap → Methods page (sources).
🔬
Medical Affairs
KOLs · Advisory boards · Trials
Read for KOL identification, advisory board composition, and the investigator landscape across Japan.
Most relevant pages
- Top 50 KOLs by recent publications
- Publication network
- Active trial landscape detail
- Strategic narrative (KOL)
- Regional KOLs & research (Part E)
- Medical Affairs deep-dive (99-100)
15-min skim
Top 50 KOLs → Publication network → Strategic narrative → Medical Affairs deep-dive.
© PurpleXtra Limited
Persona Navigator
EXECUTIVE SYNTHESIS
Treated Cases
—
Latest year
Hospitals
—
Treating centres
Tier 1 Case Share
—
Volume Trend
—
Market Snapshot
Loading…
Provider Structure
Loading…
Key Dynamics & Risks
- Loading…
Strategic Priorities
- Loading…
90-Day Action Plan
- Loading…
© PurpleXtra Limited
Executive Synthesis
Japan National Overview
Market snapshot (Japan)
Geography
Japan
Indication
—
Treated cases (Japan)
—
Hospitals treating (Japan)
—
Built from hospital discharge activity (coded ICD-10), aggregated across participating providers.
Where the burden sits (regional outliers)
Top regions by treated cases (latest)
Japan intensity
Cases per 100k population by region (latest year in dataset)
© PurpleXtra Limited
Japan National Overview · Page 1
Cases and Incidence
Japan totals
Cases
—
Cases per 100k
—
Hospitals
—
Hospitals per 100k
—
Region incidence outliers
Top & bottom regions by cases per 100k
Cases vs incidence (region scatter)
High volume ≠ high intensity
© PurpleXtra Limited
Japan National Overview · Page 2
Hospitals and Providers
Provider footprint (Japan)
Hospitals per 100k (region outliers)
Tier segmentation (Japan)
Tier 1 / Tier 2 / Tier 3 hospital counts
Tier rules are defined by annual case volume thresholds in the Tiering module.
Commercial read
Medical read
© PurpleXtra Limited
Japan National Overview · Page 3
Disease Analysis
ICD-10 breakdown
Subcodes (if present) or peer conditions
Indication context (Japan) — précis
Sourced from PMDA, MHLW, and Japanese clinical societies. Every fact carries a source URL.
Approved therapies (PMDA)
Treatment guidelines
Reimbursement context
Full Indication Context with all sources in the Japan National Detailed report (Indication context for Japan, page 9).
© PurpleXtra Limited
Japan National Overview · Page 4
Clinical Trials
Trial footprint (Japan)
Ongoing Trials (Japan)
—
Prefectures hosting trials
—
Trials by region
Where research activity concentrates
Top industry sponsors
Sponsor concentration (Japan)
© PurpleXtra Limited
Japan National Overview · Page 5
Clinical Scope & Coding
ICD-10 Definition & Code Structure
—
—
Understanding how the indication maps to ICD-10 and how codes distribute across subtypes
Clinical Scope & Coding
ICD-10 Code Definition
ICD-10 Code
—
Disease Name
—
Common Names / Acronyms
—
Number of Subcodes
—
Total Cases
—
Hospitals Treating
—
ICD-10 Hierarchy
Chapter
—
↓
Group
—
↓
Selected Code
—
Coding Context
Loading coding context...
ICD-10 codes are used internationally to classify diseases and health conditions.
Code structure and usage may vary by region and healthcare system.
© PurpleXtra Limited
Clinical Scope & Coding · Page 1
Subcode Distribution
Subcode Volume
Cases by 4-digit ICD-10 subcode
Subcode Share
Proportion of total activity
Subcode Detail
Loading subcode analysis...
© PurpleXtra Limited
Clinical Scope & Coding · Page 2
Related Codes & Coding Guidance
Peer Codes in Group
ICD-10 codes :
Group Comparison Table
Coding Guidance
Loading coding relationships...
Note: Coding practices vary by institution and region.
PurpleXtra data reflects actual coded hospital activity, not clinical diagnosis alone.
© PurpleXtra Limited
Clinical Scope & Coding · Page 3
Coding patterns across regions
Coding distribution across Japan's 8 regions
Subcode share by region
Cell colour = % of regional total. Read across each row to see how a region distributes its volume across subcodes.
Raw counts
Cases per (region × subcode). National totals in the footer row.
Regional coding insights
- Loading regional coding analysis…
© PurpleXtra Limited
Clinical Scope & Coding · Page 4
Indication context for Japan
Regulatory and clinical guidance landscape — web-sourced, all citations preserved
Approved therapies (PMDA)
Coming in a subsequent Phase 1 session.
Will list approved therapies for this indication in Japan with PMDA approval date, label changes in the last 24 months, and NHI high-cost-drug list flag where publicly stated. Every entry will carry the original source name and URL.
Will list approved therapies for this indication in Japan with PMDA approval date, label changes in the last 24 months, and NHI high-cost-drug list flag where publicly stated. Every entry will carry the original source name and URL.
Treatment guidelines
Coming in a subsequent Phase 1 session.
Will reference Japanese clinical society guidance (e.g. JLCS, JSMO) and PMDA notices with citation URLs and dates.
Will reference Japanese clinical society guidance (e.g. JLCS, JSMO) and PMDA notices with citation URLs and dates.
Reimbursement context
Coming in a subsequent Phase 1 session.
Will cover broad NHI category and high-cost-drug list inclusion where publicly stated. Note: PurpleXtra does NOT hold payer or tendering data internally; specific tender prices and HEOR submissions are out of scope. See Methods page.
Will cover broad NHI category and high-cost-drug list inclusion where publicly stated. Note: PurpleXtra does NOT hold payer or tendering data internally; specific tender prices and HEOR submissions are out of scope. See Methods page.
Note
This page is structurally placed but not yet populated. PurpleXtra's data-integrity policy requires every fact on this page to carry a source name and URL; until that web-search pipeline is live, the page deliberately shows no figures rather than placeholders that could be misread as data.
© PurpleXtra Limited
Clinical Scope & Coding · Page 5
Treated Patient Reality
Volumes, Trends & Burden Signals
—
—
Real-world hospital activity patterns showing treatment volumes, demographic distribution, and care pathways
Treated Patient Reality
Total Treated Population
Total Cases (Latest Year)
—
—
National Incidence
Cases per 100,000 Population
—
Latest available data
Total Cases by Year
Historical treatment volume trends
Key Trends Analysis
- Loading trend analysis...
© PurpleXtra Limited
Treated Patient Reality · Page 1
Regional volume trends
Yearly treated cases across Japan's 8 regions, on the same axes for direct comparison.
Yearly cases by region
One line per region. Read divergence across years to spot regions where volume is growing, declining or stable.
Regional snapshot
© PurpleXtra Limited
Treated Patient Reality · Page 1b
Regional Population Context
Population context — not cases
This page shows Japan's general population by age and sex. Disease case counts are on the previous page (Volumes & trends) and the next page (Patient journey). Case-level age/sex segmentation is not currently in the Japan dataset.
For reference
123.8M people
— treated cases
— treated cases
Population by Age Group and Sex
General regional population (not the patient cohort) — provides demographic context for incidence comparison.
Population Context Insights
- Loading population context...
Sources: Statistics Bureau of Japan (general population). Disease case counts from PurpleXtra hospital activity database.
© PurpleXtra Limited
Treated Patient Reality · Population context
Regional age-profile comparison
Age distribution across Japan's 8 regions. Each pyramid scaled to its own regional total — population magnitude shown in the KPI strip below.
Male
Female
Hokkaido
Tohoku
Kanto
Chubu
Kansai
Chugoku
Shikoku
Kyushu & Okinawa
Hokkaido
—
65+
—
Tohoku
—
65+
—
Kanto
—
65+
—
Chubu
—
65+
—
Kansai
—
65+
—
Chugoku
—
65+
—
Shikoku
—
65+
—
Kyushu+Ok.
—
65+
—
Interpretation
- Loading regional comparison…
© PurpleXtra Limited
Treated Patient Reality · Page 2b
Patient Journey & Healthcare Access
Typical Patient Journey
- Loading patient journey information...
Hospital Distribution by Tier
Treatment capacity across hospital tiers
Tier 1 Hospitals
—
High volume centers
Tier 2 Hospitals
—
Medium volume
Tier 3 Hospitals
—
Lower volume
© PurpleXtra Limited
Treated Patient Reality · Page 3
Patient Journey & Healthcare Access
Healthcare Access Analysis
- Loading healthcare access analysis...
© PurpleXtra Limited
Treated Patient Reality · Page 3b
Regional notes — patient access by region
How each of Japan's 8 regions concentrates treated cases across its hospital tiers — the access shape a field force will encounter region by region.
Values shown are concrete data points from PurpleXtra's diagnostic statistics and hospital database (see Methods). No AI-generated commentary on individual regions — for an explicit AI-synthesised access narrative covering Japan as a whole, see the previous page.
© PurpleXtra Limited
Treated Patient Reality · Page 3c
Hospital Concentration & Tiering
Provider Landscape & Market Structure
—
—
Hospital tier distribution, concentration metrics, and targeting intelligence for pharma commercial strategy
Hospital Concentration & Tiering
Total Hospitals
—
Total Cases
—
Tier 1 Case Share
—
Top 10 Case Share
—
Hospital Case Distribution (Pareto)
The Pareto curve shows cumulative case concentration. Tier I hospitals (0-70% of cases) represent high-volume centers, Tier II (70-90%) medium-volume, and Tier III (90-100%) lower-volume providers.
Tier Summary
Loading tier data...
Market Concentration Insights
- Loading strategic insights...
© PurpleXtra Limited
Hospital Concentration & Tiering · Page 1
Hospital Concentration & Tiering
Top Regions by Case Volume
Loading hospital data...
Geographic Concentration by City
Loading city data...
Account Prioritization Insights
- Loading targeting insights...
© PurpleXtra Limited
Hospital Concentration & Tiering · Page 2
Hospital Concentration & Tiering
Where capacity concentrates
- Loading…
Where capacity is thin
- Loading…
Concentration measures
- Loading…
© PurpleXtra Limited
Hospital Concentration & Tiering · Page 3
Tier composition & concentration
How national volume concentrates across the hospital tiers and the top of the long tail.
Top 10 hospitals
—
share of cases
Top 10% of hospitals
—
share of cases (90/10)
Tier 1 case share
—
≈70% by definition
Tier 1 avg cases
—
per Tier 1 hospital
Hospitals vs cases by tier
Top bar: share of hospitals by tier. Bottom bar: share of cases by tier. The gap between the two shows how concentrated treatment is in the high-volume centres.
Tier comparison
Concentration insights
- Loading concentration analysis…
© PurpleXtra Limited
Hospital Concentration & Tiering · Page 4
Regional Inequality & Access Signals
Geographic Disparities & Service Access Analysis
—
—
Identify where most patients are treated, find regions with unmet need, and deploy your team for maximum impact
Regional Inequality & Access Signals
Regions Analyzed
—
Top Region Share
—
Concentration Index
—
Regional Case Distribution
Access Inequality (Cases vs Hospitals)
© PurpleXtra Limited
Regional Inequality & Access Signals · Page 1
Regional Inequality & Access Signals
Access Inequality (Cases vs Hospitals)
Each prefecture plotted by share of hospitals (x) vs share of cases (y). Points above the diagonal indicate prefectures with relatively more cases than hospital capacity.
© PurpleXtra Limited
Regional Inequality & Access Signals · Page 1b
Regional Inequality & Access Signals
Regional Summary
Key Disparities
- Loading insights...
© PurpleXtra Limited
Regional Inequality & Access Signals · Page 2
Regional Inequality & Access Signals
City-Level Access Analysis
Top Cities by Volume
Geographic Coverage Gaps
- Loading gap analysis...
Travel Distance Implications
- Loading travel analysis...
© PurpleXtra Limited
Regional Inequality & Access Signals · Page 3
Regional Inequality & Access Signals
Hospital Capacity Pressure
High-Volume Centres
- Loading pressure analysis...
Service Expansion Opportunities
- Loading expansion analysis...
Resource Allocation Recommendations
- Loading recommendations...
© PurpleXtra Limited
Regional Inequality & Access Signals · Page 4
Key Opinion Leaders & Market Influence
Research Activity & KOL Landscape
—
—
Identify research-active sites, trial investigators, and early adopters for pre-launch engagement
Trials in Japan at a glance
Medical Affairs · Investigator landscape 🔬
Ongoing clinical trials registered on ClinicalTrials.gov with at least one site in Japan.
Ongoing trials
—
across Japan
Recent starts
—
last 12 months
Prefectures hosting
—
at least one trial site
Top 20 industry sponsors
Ranked by ongoing-trial count. Academic-led trials are excluded from this view; see the industry vs academic split on page 21.
Phase distribution
Each trial binned to its highest declared phase. "N/A" covers observational and not-applicable trials.
Landscape insights
- Loading trial landscape analysis…
Regional trial density across Japan's 8 regions on the next page.
© PurpleXtra Limited
KOL & Research Landscape · Trials in Japan at a glance
Regional trial density
Medical Affairs · Investigator landscape 🔬
Each of Japan's 8 regions coloured by the number of active trials with at least one site there.
Deeper purple = more trials. For per-region counts and the top-20 trials, see page 21.
Counts are deduplicated within a region: a multi-prefecture trial is counted once per region. Sourced live from ClinicalTrials.gov v2 API with a 24-hour cache. Regional boundaries from PurpleXtra's 8-region dissolve of the 47-prefecture source.
© PurpleXtra Limited
KOL & Research Landscape · Regional trial density
Key Opinion Leaders & Market Influence
Active Trials
—
Recent Trials
—
Started in 2025
Total Hospitals
—
© PurpleXtra Limited
Key Opinion Leaders & Market Influence · Page 1
Key Opinion Leaders & Market Influence
© PurpleXtra Limited
Key Opinion Leaders & Market Influence · Page 2
Key Opinion Leaders & Market Influence
Japan Publications
—
Total papers on disease
Region Publications
—
Total papers from region
Recent Publications
—
Last 12 months (region)
Key Opinion Leaders - Publications
© PurpleXtra Limited
Key Opinion Leaders & Market Influence · Page 3
Publication co-authorship network
Medical Affairs · Advisory Board Composition 🔬
Co-authorship structure among the top 50 Japanese KOLs from PubMed publications in the last 3 years.
Each node = one of the top 50 KOLs by publications. Node size scales with publication count. Edges connect authors who have co-authored at least one paper. Top 5 most-connected authors are labelled. The full top-50 list, with names and institutions, is enumerated on pages 19A–D.
Network insights
- Loading co-authorship analysis…
© PurpleXtra Limited
KOL & Research Landscape · Publication network
Active trial landscape detail
Medical Affairs · Commercial 🔬
Regional distribution and sponsor profile. Top-20 recruiting trials follow on the next page.
Trials by region
Ongoing trials per region with a recent-starts subline. Counts deduplicated across prefectures within a region (a multi-prefecture trial is counted once per region).
Industry vs academic sponsorship
Split over all ongoing trials. Industry classification follows ClinicalTrials.gov's leadSponsor.class field — academic-led trials with industry collaborators are counted as academic here.
© PurpleXtra Limited
KOL & Research Landscape · Active trial landscape
Top recruiting trials
Medical Affairs · Commercial 🔬
Ranked: recruiting first, then by recency and Japanese footprint (prefecture count). "Recent" flags trials that started in the last 12 months.
Top 20 trials by recruitment priority
Investigator-led, industry-collaborator, and pharma-sponsored studies all included.
© PurpleXtra Limited
KOL & Research Landscape · Top recruiting trials
Strategic narrative — KOL & advisory board composition
Medical Affairs · Advisory Board Composition 🔬
Synthesis of the KOL ranking, publication network, and trial-investigator landscape — the inputs to advisory board design and Japanese launch sequencing.
Strategic synthesis
© PurpleXtra Limited
KOL & Research Landscape · Strategic narrative
E1 · Regional Dossier
KANTO — REGIONAL OVERVIEW
Kanto
Region location
Headline figures
Population
—
residents
Reporting hospitals
—
all tiers
Cases
—
reported period
Share of national
—
of total cases
Cases / 100k
—
incidence proxy
Hospitals / 100k
—
capacity proxy
Hospital tiering · Kanto
Reporting hospitals split by case-volume tier — all hospitals, not top-50 only.
Kanto's share of national
Tier I (high volume)
—
Tier II
—
Tier III
—
Kanto vs Japan · normalised view
| Metric | Kanto | Japan |
|---|---|---|
| Cases per 100k residents | — | — |
| Reporting hospitals per 100k | — | — |
| Total reporting hospitals | — | — |
—
© PurpleXtra Limited
Regional Dossier · Kanto · Overview
E1 · Regional Dossier
KANTO — DEMOGRAPHICS
Population structure for the Kanto region
Total population
—
Aged 65 and above
—
Share of national
—
Age distribution
Gender split
Male
—
Female
—
—
© PurpleXtra Limited
Regional Dossier · Kanto · Demographics
E1 · Regional Dossier
KANTO — HOSPITAL LANDSCAPE
Tier composition and leading facilities in the Kanto region
Reporting hospitals
—
Tier-1 hospitals
—
Tier-1 share
—
Region share of national
—
Leading hospitals in Kanto (top 10 by case volume)
| # | Hospital | Prefecture | Cases |
|---|
Case concentration by Kanto prefecture
Leading cities in Kanto
| City | Prefecture | Cases |
|---|
—
© PurpleXtra Limited
Regional Dossier · Kanto · Hospital landscape
E1 · Regional Dossier
KANTO — TREATMENT VOLUMES & TRENDS
Reported case trajectory for the Kanto region
Cases — period total
—
Most recent year
—
CAGR (period)
—
Share of national
—
Cases per Kanto prefecture — annual stacked
© PurpleXtra Limited
Regional Dossier · Kanto · Treatment volumes
E1 · Regional Dossier
CHUBU — REGIONAL OVERVIEW
Chubu
Region location
Headline figures
Population
—
residents
Reporting hospitals
—
all tiers
Cases
—
reported period
Share of national
—
of total cases
Cases / 100k
—
incidence proxy
Hospitals / 100k
—
capacity proxy
Hospital tiering · Chubu
Reporting hospitals split by case-volume tier — all hospitals, not top-50 only.
Chubu's share of national
Tier I (high volume)
—
Tier II
—
Tier III
—
Chubu vs Japan · normalised view
| Metric | Chubu | Japan |
|---|---|---|
| Cases per 100k residents | — | — |
| Reporting hospitals per 100k | — | — |
| Total reporting hospitals | — | — |
—
© PurpleXtra Limited
Regional Dossier · Chubu · Overview
E1 · Regional Dossier
CHUBU — DEMOGRAPHICS
Population structure for the Chubu region
Total population
—
Aged 65 and above
—
Share of national
—
Age distribution
Gender split
Male
—
Female
—
—
© PurpleXtra Limited
Regional Dossier · Chubu · Demographics
E1 · Regional Dossier
CHUBU — HOSPITAL LANDSCAPE
Tier composition and leading facilities in the Chubu region
Reporting hospitals
—
Tier-1 hospitals
—
Tier-1 share
—
Region share of national
—
Leading hospitals in Chubu (top 10 by case volume)
| # | Hospital | Prefecture | Cases |
|---|
Case concentration by Chubu prefecture
Leading cities in Chubu
| City | Prefecture | Cases |
|---|
—
© PurpleXtra Limited
Regional Dossier · Chubu · Hospital landscape
E1 · Regional Dossier
CHUBU — TREATMENT VOLUMES & TRENDS
Reported case trajectory for the Chubu region
Cases — period total
—
Most recent year
—
CAGR (period)
—
Share of national
—
Cases per Chubu prefecture — annual stacked
© PurpleXtra Limited
Regional Dossier · Chubu · Treatment volumes
E1 · Regional Dossier
KANSAI — REGIONAL OVERVIEW
Kansai
Region location
Headline figures
Population
—
residents
Reporting hospitals
—
all tiers
Cases
—
reported period
Share of national
—
of total cases
Cases / 100k
—
incidence proxy
Hospitals / 100k
—
capacity proxy
Hospital tiering · Kansai
Reporting hospitals split by case-volume tier — all hospitals, not top-50 only.
Kansai's share of national
Tier I (high volume)
—
Tier II
—
Tier III
—
Kansai vs Japan · normalised view
| Metric | Kansai | Japan |
|---|---|---|
| Cases per 100k residents | — | — |
| Reporting hospitals per 100k | — | — |
| Total reporting hospitals | — | — |
—
© PurpleXtra Limited
Regional Dossier · Kansai · Overview
E1 · Regional Dossier
KANSAI — DEMOGRAPHICS
Population structure for the Kansai region
Total population
—
Aged 65 and above
—
Share of national
—
Age distribution
Gender split
Male
—
Female
—
—
© PurpleXtra Limited
Regional Dossier · Kansai · Demographics
E1 · Regional Dossier
KANSAI — HOSPITAL LANDSCAPE
Tier composition and leading facilities in the Kansai region
Reporting hospitals
—
Tier-1 hospitals
—
Tier-1 share
—
Region share of national
—
Leading hospitals in Kansai (top 10 by case volume)
| # | Hospital | Prefecture | Cases |
|---|
Case concentration by Kansai prefecture
Leading cities in Kansai
| City | Prefecture | Cases |
|---|
—
© PurpleXtra Limited
Regional Dossier · Kansai · Hospital landscape
E1 · Regional Dossier
KANSAI — TREATMENT VOLUMES & TRENDS
Reported case trajectory for the Kansai region
Cases — period total
—
Most recent year
—
CAGR (period)
—
Share of national
—
Cases per Kansai prefecture — annual stacked
© PurpleXtra Limited
Regional Dossier · Kansai · Treatment volumes
E1 · Regional Dossier
TOHOKU — REGIONAL OVERVIEW
Tohoku
Region location
Headline figures
Population
—
residents
Reporting hospitals
—
all tiers
Cases
—
reported period
Share of national
—
of total cases
Cases / 100k
—
incidence proxy
Hospitals / 100k
—
capacity proxy
Hospital tiering · Tohoku
Reporting hospitals split by case-volume tier — all hospitals, not top-50 only.
Tohoku's share of national
Tier I (high volume)
—
Tier II
—
Tier III
—
Tohoku vs Japan · normalised view
| Metric | Tohoku | Japan |
|---|---|---|
| Cases per 100k residents | — | — |
| Reporting hospitals per 100k | — | — |
| Total reporting hospitals | — | — |
—
© PurpleXtra Limited
Regional Dossier · Tohoku · Overview
E1 · Regional Dossier
TOHOKU — DEMOGRAPHICS
Population structure for the Tohoku region
Total population
—
Aged 65 and above
—
Share of national
—
Age distribution
Gender split
Male
—
Female
—
—
© PurpleXtra Limited
Regional Dossier · Tohoku · Demographics
E1 · Regional Dossier
TOHOKU — HOSPITAL LANDSCAPE
Tier composition and leading facilities in the Tohoku region
Reporting hospitals
—
Tier-1 hospitals
—
Tier-1 share
—
Region share of national
—
Leading hospitals in Tohoku (top 10 by case volume)
| # | Hospital | Prefecture | Cases |
|---|
Case concentration by Tohoku prefecture
Leading cities in Tohoku
| City | Prefecture | Cases |
|---|
—
© PurpleXtra Limited
Regional Dossier · Tohoku · Hospital landscape
E1 · Regional Dossier
TOHOKU — TREATMENT VOLUMES & TRENDS
Reported case trajectory for the Tohoku region
Cases — period total
—
Most recent year
—
CAGR (period)
—
Share of national
—
Cases per Tohoku prefecture — annual stacked
© PurpleXtra Limited
Regional Dossier · Tohoku · Treatment volumes
E1 · Regional Dossier
KYUSHU & OKINAWA — REGIONAL OVERVIEW
Kyushu & Okinawa
Region location
Headline figures
Population
—
residents
Reporting hospitals
—
all tiers
Cases
—
reported period
Share of national
—
of total cases
Cases / 100k
—
incidence proxy
Hospitals / 100k
—
capacity proxy
Hospital tiering · Kyushu & Okinawa
Reporting hospitals split by case-volume tier — all hospitals, not top-50 only.
Kyushu & Okinawa's share of national
Tier I (high volume)
—
Tier II
—
Tier III
—
Kyushu & Okinawa vs Japan · normalised view
| Metric | Kyushu & Okinawa | Japan |
|---|---|---|
| Cases per 100k residents | — | — |
| Reporting hospitals per 100k | — | — |
| Total reporting hospitals | — | — |
—
© PurpleXtra Limited
Regional Dossier · Kyushu & Okinawa · Overview
E1 · Regional Dossier
KYUSHU & OKINAWA — DEMOGRAPHICS
Population structure for the Kyushu & Okinawa region
Total population
—
Aged 65 and above
—
Share of national
—
Age distribution
Gender split
Male
—
Female
—
—
© PurpleXtra Limited
Regional Dossier · Kyushu & Okinawa · Demographics
E1 · Regional Dossier
KYUSHU & OKINAWA — HOSPITAL LANDSCAPE
Tier composition and leading facilities in the Kyushu & Okinawa region
Reporting hospitals
—
Tier-1 hospitals
—
Tier-1 share
—
Region share of national
—
Leading hospitals in Kyushu & Okinawa (top 10 by case volume)
| # | Hospital | Prefecture | Cases |
|---|
Case concentration by Kyushu & Okinawa prefecture
Leading cities in Kyushu & Okinawa
| City | Prefecture | Cases |
|---|
—
© PurpleXtra Limited
Regional Dossier · Kyushu & Okinawa · Hospital landscape
E1 · Regional Dossier
KYUSHU & OKINAWA — TREATMENT VOLUMES & TRENDS
Reported case trajectory for the Kyushu & Okinawa region
Cases — period total
—
Most recent year
—
CAGR (period)
—
Share of national
—
Cases per Kyushu & Okinawa prefecture — annual stacked
© PurpleXtra Limited
Regional Dossier · Kyushu & Okinawa · Treatment volumes
E1 · Regional Dossier
CHUGOKU — REGIONAL OVERVIEW
Chugoku
Region location
Headline figures
Population
—
residents
Reporting hospitals
—
all tiers
Cases
—
reported period
Share of national
—
of total cases
Cases / 100k
—
incidence proxy
Hospitals / 100k
—
capacity proxy
Hospital tiering · Chugoku
Reporting hospitals split by case-volume tier — all hospitals, not top-50 only.
Chugoku's share of national
Tier I (high volume)
—
Tier II
—
Tier III
—
Chugoku vs Japan · normalised view
| Metric | Chugoku | Japan |
|---|---|---|
| Cases per 100k residents | — | — |
| Reporting hospitals per 100k | — | — |
| Total reporting hospitals | — | — |
—
© PurpleXtra Limited
Regional Dossier · Chugoku · Overview
E1 · Regional Dossier
CHUGOKU — DEMOGRAPHICS
Population structure for the Chugoku region
Total population
—
Aged 65 and above
—
Share of national
—
Age distribution
Gender split
Male
—
Female
—
—
© PurpleXtra Limited
Regional Dossier · Chugoku · Demographics
E1 · Regional Dossier
CHUGOKU — HOSPITAL LANDSCAPE
Tier composition and leading facilities in the Chugoku region
Reporting hospitals
—
Tier-1 hospitals
—
Tier-1 share
—
Region share of national
—
Leading hospitals in Chugoku (top 10 by case volume)
| # | Hospital | Prefecture | Cases |
|---|
Case concentration by Chugoku prefecture
Leading cities in Chugoku
| City | Prefecture | Cases |
|---|
—
© PurpleXtra Limited
Regional Dossier · Chugoku · Hospital landscape
E1 · Regional Dossier
CHUGOKU — TREATMENT VOLUMES & TRENDS
Reported case trajectory for the Chugoku region
Cases — period total
—
Most recent year
—
CAGR (period)
—
Share of national
—
Cases per Chugoku prefecture — annual stacked
© PurpleXtra Limited
Regional Dossier · Chugoku · Treatment volumes
E1 · Regional Dossier
SHIKOKU — REGIONAL OVERVIEW
Shikoku
Region location
Headline figures
Population
—
residents
Reporting hospitals
—
all tiers
Cases
—
reported period
Share of national
—
of total cases
Cases / 100k
—
incidence proxy
Hospitals / 100k
—
capacity proxy
Hospital tiering · Shikoku
Reporting hospitals split by case-volume tier — all hospitals, not top-50 only.
Shikoku's share of national
Tier I (high volume)
—
Tier II
—
Tier III
—
Shikoku vs Japan · normalised view
| Metric | Shikoku | Japan |
|---|---|---|
| Cases per 100k residents | — | — |
| Reporting hospitals per 100k | — | — |
| Total reporting hospitals | — | — |
—
© PurpleXtra Limited
Regional Dossier · Shikoku · Overview
E1 · Regional Dossier
SHIKOKU — DEMOGRAPHICS
Population structure for the Shikoku region
Total population
—
Aged 65 and above
—
Share of national
—
Age distribution
Gender split
Male
—
Female
—
—
© PurpleXtra Limited
Regional Dossier · Shikoku · Demographics
E1 · Regional Dossier
SHIKOKU — HOSPITAL LANDSCAPE
Tier composition and leading facilities in the Shikoku region
Reporting hospitals
—
Tier-1 hospitals
—
Tier-1 share
—
Region share of national
—
Leading hospitals in Shikoku (top 10 by case volume)
| # | Hospital | Prefecture | Cases |
|---|
Case concentration by Shikoku prefecture
Leading cities in Shikoku
| City | Prefecture | Cases |
|---|
—
© PurpleXtra Limited
Regional Dossier · Shikoku · Hospital landscape
E1 · Regional Dossier
SHIKOKU — TREATMENT VOLUMES & TRENDS
Reported case trajectory for the Shikoku region
Cases — period total
—
Most recent year
—
CAGR (period)
—
Share of national
—
Cases per Shikoku prefecture — annual stacked
© PurpleXtra Limited
Regional Dossier · Shikoku · Treatment volumes
METHODS & DATA SOURCES
Transparency note — how this report was built
Data Provenance
All quantitative outputs in this report derive from structured, auditable data sources. No case counts, hospital figures, or tier assignments are estimated, projected, or modelled. Diagnostic statistics are obtained from national and regional government bodies and hospital organisations, accessed using the national Freedom of Information legislation in Japan. Hospital records are drawn from PurpleXtra's proprietary hospital database, where every facility has been individually researched and verified.
| Data Domain | Primary Source | Scope | Access Method |
|---|---|---|---|
| Diagnostic statistics | National & regional government health agencies; hospital organisations | ICD-10 coded hospital activity across 8 Japanese regions (47 prefectures); annual volumes by facility | Freedom of Information requests under national Japanese information disclosure |
| Hospital database | PurpleXtra proprietary hospital database | Name, address, region, bed count, contact details; every hospital individually researched | Continuous primary research; validated quarterly |
| Population statistics | Japan Statistics Bureau | Total population by region and age/sex for incidence rate calculation | Published open data; annual updates |
| Clinical trials | ClinicalTrials.gov v2 API (U.S. National Library of Medicine) | Registered trials by MeSH condition; status, sponsors, regional site locations | Live API; results cached 24 hours |
| Publication & KOL analysis | PubMed / MEDLINE via NCBI E-utilities API | Indexed peer-reviewed publications; author affiliations; last 12 months focus | Live API; results cached 24 hours |
| Disease taxonomy | WHO ICD-10 classification; NLM MeSH vocabulary | Code-to-description mapping; MeSH linkage for trial & publication queries | Versioned; updated with WHO releases |
| Treatment landscape | Clinical guidelines (Japanese clinical guidelines, PMDA); published literature | Japanese treatment patterns, approved therapies, standard-of-care protocols | AI-synthesised from published clinical sources; cited in report |
Hospital Tiering Methodology
Hospitals are ranked by descending case volume. Tier I comprises the fewest hospitals whose cumulative caseload reaches 70% of the national total. Tier II extends coverage to 90%. Tier III contains the remaining long-tail facilities. Thresholds are applied consistently across Japan, enabling direct cross-market comparison of provider concentration.
AI-Assisted Analysis
Narrative insights, strategic commentary, and the Executive Synthesis are generated by Anthropic Claude, prompted exclusively with the structured data presented in this report. The model does not inject external assumptions. Treatment landscape summaries are AI-synthesised from published clinical guidelines and peer-reviewed sources, which are cited individually within the relevant report sections.
Coverage & Known Limitations
The Japan data (All 8 regions of Japan) covers approximately 85% of the Japanese pharmaceutical market by value.
Diagnostic data captures treated inpatient episodes and may under-represent outpatient-only management or private-sector activity. Data availability may vary between regions depending on FOI response timelines. Multi-region clinical trials are counted once per region but deduplicated in pan-Japan totals.
© PurpleXtra Limited
Methods & Data Sources
PurpleXtra Limited
Email: bob@purplextra.com
Web: www.purplextra.com
Registered in England & Wales · Company No. 13518421
© PurpleXtra Limited. All rights reserved.
Trial mode
Full reports require a subscription
You're browsing PurpleXtra Japan in trial mode. To generate a full regional or national report — with hospital-level data, tiering analysis and KOL influence — please log in or view pricing.
Want to see what's inside? Download our free Cystic Fibrosis — Kanto sample report.
Free sample
Generating Report
Initialising…
0 %